From GlobeNewswire: 2024-07-30 07:30:00

Day One Biopharmaceuticals reported $8.2 million in OJEMDATM net product revenues in the first 2 months of launch. They also added a potential first-in-class Antibody Drug Conjugate (ADC) targeting PTK7 to their pipeline. The company entered a licensing agreement with Ipsen for tovorafenib outside the U.S. for $111 million.

Day One announced outstanding Q2 results, including FDA accelerated approval of OJEMDA for pediatric low-grade glioma. They presented data from the Phase 2 FIREFLY-1 trial, showing a median treatment duration of 23.7 months for patients. A licensing agreement with MabCare Therapeutics for a novel ADC targeting PTK7 was also finalized.

The company made significant advances in its pipeline, closing the pimasertib program to focus on DAY301. Key financial highlights included $361.9 million in cash, $8.2 million in OJEMDA sales, and increased R&D and SG&A expenses. Day One also completed a private placement offering worth $175 million and sold a Priority Review Voucher for $108 million.

Upcoming milestones include participation in the 2024 Wedbush PacGrow Healthcare Conference and a conference call on July 30. OJEMDA, a Type II RAF kinase inhibitor for pediatric low-grade glioma, has received FDA Breakthrough Therapy and Rare Pediatric Disease designations. Day One aims to transform cancer treatment starting from “Day One.”



Read more at GlobeNewswire:: Day One Reports Second Quarter 2024 Financial Results and